Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhenjing Dingzhi Granule is a Traditional Chinese Medicine (TCM) herbal formulation developed by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is designed to treat insomnia associated with depressive disorders by applying the TCM principles of calming the spirit (An Shen) and stabilizing the mind (Ding Zhi). The granule is currently being evaluated in clinical trials as an adjunctive therapy to the selective serotonin reuptake inhibitor (SSRI) fluoxetine. The research focuses on its ability to improve sleep quality, specifically targeting REM sleep parameters as measured by polysomnography, and reducing the severity of depressive symptoms in patients with mild to moderate depression-related insomnia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhenjing Dingzhi Granule.